LAS VEGAS — In this Healio Video Perspective, Tarek S. Hassan, MD, professor of ophthalmology at Oakland University William Beaumont Hospital, discusses the results of a phase 2a study of AVD-104 for geographic atrophy.
Eighty-four percent of eyes that received a clinical dose of AVD-104 (Aviceda Therapeutics) experienced visual improvement of five or more letters after one intravitreal injection at 3 months. AVD-104 also slowed the growth of GA lesions by nearly 50%.
“The entire phase 2a trial showed overall anatomic and functional improvement with AVD-104 for treating GA in (Read more...)